title: [A case of a 14-month survival patient on advanced esophageal cancer with uncontrolled brain metastasis completely responding to nedaplatin, adriamycin, plus 5-FU (NAF) therapy].
abstract: This case was a male patient, about 50 years old. He received a curative operation for advanced esophageal carcinoma [poorly differentiated squamous cell carcinoma type, Lt, pT3 (pAd) pN3, pstage III] in March 2005. He also received adjuvant chemotherapy of 5-FU plus cisplatin (CDDP). Fourteen months later (May 2006) from surgery, metastases to the left lung and left subclavian lymph nodes were diagnosed, so he received first-line triplet combination chemotherapy (NAF regimen; nedaplatin 60 mg/m2: day 1, adriamycin 50 mg/m2: day 1, 5-FU 700 mg/m2: day 1-5). According to the 9 courses of treatment of this regimen, complete response for these metastases was observed and first-line chemotherapy was finished. However, a severe headache appeared 3 months later, and he had a diagnosis of solitary 5 cm brain metastasis by MRI. Excision of the metastasis was performed with sequential whole-brain radiation therapy (30 Gy). Five months later, diffuse and multiple brain metastases relapsed, and second-line chemotherapy did not respond well, and finally he was died 3 months after palliative care. But, completely controlled metastases (lung and lymph node) by first-line chemotherapy did not relapse again in all his clinical period. If an anticancer therapy goes in complete response in an advanced esophageal carcinoma patient, we should consider about a rare brain metastasis in order to find out as small and solitary state.
authors.affiliation: Department of Surgery, Minoh City Hospital.
authors.forename: Shohei
authors.initials: S
authors.lastname: Iijima
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Makari
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kato
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ooshima
authors.forename: Minako
authors.initials: M
authors.lastname: Hoshi
authors.forename: Takashi
authors.initials: T
authors.lastname: Doi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Miyake
authors.forename: Takuya
authors.initials: T
authors.lastname: Sakamoto
authors.forename: Aya
authors.initials: A
authors.lastname: Kato
authors.forename: Masaaki
authors.initials: M
authors.lastname: Miyo
authors.forename: Eiji
authors.initials: E
authors.lastname: Kurokawa
authors.forename: Nobuteru
authors.initials: N
authors.lastname: Kikkawa
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000556:secondary*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004317:Doxorubicin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D004317:Doxorubicin; C053989:nedaplatin; D005472:Fluorouracil